Oerth’s unique PROTAC® protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products /…
Pathalys Pharma, the Research Triangle Park-based biopharmaceutical company developing therapies for end-stage kidney disease, has secured $150 million in new…
Gene therapy company Asklepios BioPharmaceutical (AskBio) of Research Triangle Park has signed a multi-year research collaboration and option agreement with…